APA (7th ed.) Citation

André, T., Tougeron, D., Piessen, G., de la Fouchardière, C., Louvet, C., Adenis, A., . . . Svrcek, M. (2023). Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. Journal of clinical oncology, 41(2), 255-265. https://doi.org/10.1200/JCO.22.00686

Chicago Style (17th ed.) Citation

André, Thierry, et al. "Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study." Journal of Clinical Oncology 41, no. 2 (2023): 255-265. https://doi.org/10.1200/JCO.22.00686.

MLA (9th ed.) Citation

André, Thierry, et al. "Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study." Journal of Clinical Oncology, vol. 41, no. 2, 2023, pp. 255-265, https://doi.org/10.1200/JCO.22.00686.